Choi, JungMin
Lee, So‑Ryoung
Choi, Eue-Keun
Lee, Kyung-Yeon
Ahn, Hyo-Jeong
Kwon, Soonil
Han, Kyung‑Do
Oh, Seil
Lip, Gregory Y. H.
Funding for this research was provided by:
Patient-Centered Clinical Research Coordinating Center (HC21C0028)
Korea Medical Device Development Fund grant (HI20C1662, 1711138358, KMDF_PR_20200901_0173)
Article History
Received: 20 November 2023
Accepted: 10 March 2024
First Online: 30 March 2024
Declarations
:
: The study adhered to the principles outlined in the Declaration of Helsinki. The data were anonymized; therefore, they were exempt from review by the Institutional Review Board (IRB) of Seoul National University Hospital (IRB no. E-2307-129-1452). Additionally, obtaining informed consent was not possible because the data from the NHIS were de-identified. The utilization of the NHIS database from 2015 to 2020 was authorized in 2023.
: Not applicable.
: SRL: Speaking fees from Bayer, BMS/Pfizer, Biosense Webster, Daiichi-Sankyo, Sanofi-Aventis, Daewoong Pharmaceutical Co., Samjinpharm, Seers Technology, Biotronik, Boston Scientific, and Medtronic. Consultant for Biosense Webster. EKC: Research grants or speaking fees from Abbott, Bayer, BMS/Pfizer, Biosense Webster, Chong Kun Dang, Daewoong Pharmaceutical Co., Daiichi-Sankyo, DeepQure, Dreamtech Co., Ltd., Jeil Pharmaceutical Co. Ltd., Medtronic, Samjin Pharm, Seers Technology, and Skylabs. GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Anthos, and Daiichi-Sankyo. GYHL is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 899871. No personal fees were received. The remaining authors have nothing to disclose.